NASDAQ:GOSSGossamer Bio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gossamer Bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.15 +0.05 (+0.41 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$11.41Now: $12.15▼$12.2550-Day Range$11.10MA: $12.90▼$15.9852-Week Range$7.52Now: $12.15▼$27.15Volume939,605 shsAverage Volume963,900 shsMarket Capitalization$806.27 millionP/E RatioN/ADividend YieldN/ABeta1.21 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingGossamer Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.29, Gossamer Bio has a potential upside of 141.0% from its current price of $12.15.Amount of Analyst CoverageGossamer Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesGossamer Bio has received 88 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGossamer Bio has received 96 “underperform” votes. (Add your “underperform” vote.)Community SentimentGossamer Bio has received 52.17% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Gossamer Bio and other stocks. Vote “Outperform” if you believe GOSS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GOSS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 23.30% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions58.13% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($3.38) to ($3.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GOSS Previous Symbol CUSIPN/A CIKN/A Webwww.gossamerbio.com Phone858-922-0718Debt Debt-to-Equity Ratio0.12 Current Ratio12.53 Quick Ratio12.53Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.62 per share Price / Book2.63Profitability EPS (Most Recent Fiscal Year)($3.29) Net Income$-180,310,000.00 Net MarginsN/A Return on Equity-53.83% Return on Assets-45.47%Miscellaneous Employees118 Outstanding Shares66,360,000Market Cap$806.27 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:GOSS Rates by TradingView Receive GOSS News and Ratings via Email Sign-up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Gossamer Bio (NASDAQ:GOSS) Frequently Asked Questions How has Gossamer Bio's stock been impacted by COVID-19 (Coronavirus)? Gossamer Bio's stock was trading at $10.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GOSS shares have increased by 14.7% and is now trading at $12.15. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Gossamer Bio? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gossamer Bio. When is Gossamer Bio's next earnings date? Gossamer Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Gossamer Bio. How were Gossamer Bio's earnings last quarter? Gossamer Bio Inc (NASDAQ:GOSS) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.80) by $0.07. View Gossamer Bio's earnings history. What price target have analysts set for GOSS? 7 brokerages have issued twelve-month price objectives for Gossamer Bio's stock. Their forecasts range from $21.00 to $36.00. On average, they expect Gossamer Bio's share price to reach $29.29 in the next twelve months. This suggests a possible upside of 141.0% from the stock's current price. View analysts' price targets for Gossamer Bio. Has Gossamer Bio been receiving favorable news coverage? Press coverage about GOSS stock has been trending positive on Monday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gossamer Bio earned a news impact score of 2.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutGossamer Bio. Are investors shorting Gossamer Bio? Gossamer Bio saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 4,730,000 shares, a drop of 5.8% from the April 30th total of 5,020,000 shares. Based on an average daily volume of 403,500 shares, the short-interest ratio is currently 11.7 days. Currently, 10.8% of the shares of the stock are sold short. View Gossamer Bio's Current Options Chain. Who are some of Gossamer Bio's key competitors? Some companies that are related to Gossamer Bio include Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), Allakos (ALLK), Arena Pharmaceuticals (ARNA), FibroGen (FGEN), Uniqure (QURE), HUTCHISON CHINA/S (HCM), Axsome Therapeutics (AXSM), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Insmed (INSM) and Karuna Therapeutics (KRTX). View all competitors. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Tcr2 Therapeutics (TCRR), Precision BioSciences (DTIL), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), II-VI (IIVI), Kaleido Biosciences (KLDO), Akero Therapeutics (AKRO) and Crispr Therapeutics (CRSP). Who are Gossamer Bio's key executives? Gossamer Bio's management team includes the following people: Mr. Faheem Hasnain, Co-Founder & Exec. Chairman (Age 61)Dr. Sheila K. Gujrathi M.D., Co-Founder, Pres, CEO & Director (Age 49)Mr. Bryan Giraudo, Chief Financial Officer (Age 43)Mr. Christian Waage, Exec. VP, Gen. Counsel & Sec. (Age 52)Dr. Jakob Dupont, Chief Medical Officer (Age 54) When did Gossamer Bio IPO? (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. What is Gossamer Bio's stock symbol? Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS." Who are Gossamer Bio's major shareholders? Gossamer Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.29%), Alliancebernstein L.P. (2.77%), State Street Corp (2.50%), Federated Hermes Inc. (2.29%), Victory Capital Management Inc. (2.10%) and Victory Capital Management Inc. (2.10%). Company insiders that own Gossamer Bio stock include Bryan Giraudo, Faheem Hasnain, Fund V Gp LP Omega, Jakob Dupont, Luisa Salter-Cid, Russell J Cox and Waage Christian. View institutional ownership trends for Gossamer Bio. Which institutional investors are selling Gossamer Bio stock? GOSS stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Cormorant Asset Management LP, Ensign Peak Advisors Inc, BlackRock Inc., Russell Investments Group Ltd., UBS Group AG, Squarepoint Ops LLC, and Alps Advisors Inc.. Company insiders that have sold Gossamer Bio company stock in the last year include Fund V Gp LP Omega, Jakob Dupont, and Luisa Salter-Cid. View insider buying and selling activity for Gossamer Bio. Which institutional investors are buying Gossamer Bio stock? GOSS stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Victory Capital Management Inc., Victory Capital Management Inc., Morgan Stanley, Alyeska Investment Group L.P., Alliancebernstein L.P., Geode Capital Management LLC, and GSA Capital Partners LLP. Company insiders that have bought Gossamer Bio stock in the last two years include Bryan Giraudo, Faheem Hasnain, Russell J Cox, and Waage Christian. View insider buying and selling activity for Gossamer Bio. How do I buy shares of Gossamer Bio? Shares of GOSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Gossamer Bio's stock price today? One share of GOSS stock can currently be purchased for approximately $12.15. How big of a company is Gossamer Bio? Gossamer Bio has a market capitalization of $806.27 million. The company earns $-180,310,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Gossamer Bio employs 118 workers across the globe. What is Gossamer Bio's official website? The official website for Gossamer Bio is www.gossamerbio.com. How can I contact Gossamer Bio? Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company can be reached via phone at 858-922-0718. This page was last updated on 6/1/2020 by MarketBeat.com Staff
